Thomas Meyer

List of Publications by Year
in descending order

49 papers	3,185 citations	236925 25 h-index	168389 53 g-index
57 all docs	57 docs citations	57 times ranked	4942 citing authors

#	Article	IF	Citations
1	Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nature Neuroscience, 2015, 18, 631-636.	14.8	652
2	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1043-1048.	21.4	494
3	Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nature Genetics, 2009, 41, 1083-1087.	21.4	344
4	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648.	21.4	223
5	Hot-spot KIF5A mutations cause familial ALS. Brain, 2018, 141, 688-697.	7.6	167
6	Alterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosis. Brain, 2016, 139, 1106-1122.	7.6	80
7	Comprehensive analysis of the mutation spectrum in 301 German ALS families. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 817-827.	1.9	80
8	Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis. JAMA Neurology, 2022, 79, 121.	9.0	78
9	Online assessment of ALS functional rating scale compares well to in-clinic evaluation: A prospective trial. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 210-216.	2.1	70
10	Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 112-119.	1.7	63
11	Interleukin-1 Antagonist Anakinra in Amyotrophic Lateral Sclerosisâ€"A Pilot Study. PLoS ONE, 2015, 10, e0139684.	2.5	53
12	Early-onset ALS with long-term survival associated with spastin gene mutation. Neurology, 2005, 65, 141-143.	1.1	50
13	Live and let die: existential decision processes in a fatal disease. Journal of Neurology, 2014, 261, 518-525.	3.6	49
14	Prognostic factors in ALS: a comparison between Germany and China. Journal of Neurology, 2019, 266, 1516-1525.	3.6	46
15	Safety, Pharmacokinetic, and Functional Effects of the Nogo-A Monoclonal Antibody in Amyotrophic Lateral Sclerosis: A Randomized, First-In-Human Clinical Trial. PLoS ONE, 2014, 9, e97803.	2.5	45
16	Severe Loss of Appetite in Amyotrophic Lateral Sclerosis Patients: Online Self-Assessment Study. Interactive Journal of Medical Research, 2013, 2, e8.	1.4	42
17	Effect of high-caloric nutrition on serum neurofilament light chain levels in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1007-1009.	1.9	36
18	Therapeutic decisions in ALS patients: cross-cultural differences and clinical implications. Journal of Neurology, 2018, 265, 1600-1606.	3.6	34

#	Article	IF	Citations
19	Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD). BMC Neurology, 2019, 19, 222.	1.8	34
20	Provision of assistive technology devices among people with ALS in Germany: a platform-case management approach. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 342-350.	1.7	33
21	The glial glutamate transporter complementary DNA in patients with amyotrophic lateral sclerosis. Annals of Neurology, 1996, 40, 456-459.	5.3	30
22	Thalidomide causes sinus bradycardia in ALS. Journal of Neurology, 2008, 255, 587-591.	3.6	29
23	The metabolic and endocrine characteristics in spinal and bulbar muscular atrophy. Journal of Neurology, 2018, 265, 1026-1036.	3.6	29
24	Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment. Annals of Clinical and Translational Neurology, 2021, 8, 1049-1063.	3.7	29
25	Clinical characteristics and course of dying in patients with amyotrophic lateral sclerosis withdrawing from long-term ventilation. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 53-59.	1.7	26
26	Patient-Reported Outcome of Physical Therapy in Amyotrophic Lateral Sclerosis: Observational Online Study. JMIR Rehabilitation and Assistive Technologies, 2018, 5, e10099.	2.2	26
27	Differential regulation of 5â€² splice variants of the glutamate transporter EAAT2 in an in vivo model of chemical hypoxia induced by 3-nitropropionic acid. Journal of Neuroscience Research, 2003, 71, 819-825.	2.9	25
28	Nonâ€invasive and tracheostomy invasive ventilation in amyotrophic lateral sclerosis: Utilization and survival rates in a cohort study over 12 years in Germany. European Journal of Neurology, 2021, 28, 1160-1171.	3.3	25
29	Ifosfamide encephalopathy presenting with asterixis. Journal of the Neurological Sciences, 2002, 199, 85-88.	0.6	23
30	Breakpoint Cloning and Haplotype Analysis Indicate a Single Origin of the Common Inv(10)(p11.2q21.2) Mutation among Northern Europeans. American Journal of Human Genetics, 2006, 78, 878-883.	6.2	23
31	Differential RNA cleavage and polyadenylation of the glutamate transporter EAAT2 in the human brain. Molecular Brain Research, 2000, 80, 244-251.	2.3	21
32	Heterozygous S44L missense change of the spastin gene in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 251-253.	2.1	20
33	High rate of constitutional chromosomal rearrangements in apparently sporadic ALS. Neurology, 2003, 60, 1348-1350.	1.1	18
34	Analysis of the KIFAP3 gene in amyotrophic lateral sclerosis: a multicenter survival study. Neurobiology of Aging, 2014, 35, 2420.e13-2420.e14.	3.1	16
35	Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen. European Journal of Neurology, 2021, 28, 2582-2595.	3.3	16
36	Symptomatic pharmacotherapy in ALS: data analysis from a platform-based medication management programme. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 783-785.	1.9	15

#	Article	IF	Citations
37	A mapping review of international guidance on the management and care of amyotrophic lateral sclerosis (ALS). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 325-336.	1.7	14
38	Chemical Hypoxia Facilitates Alternative Splicing of EAAT2 in Presymptomatic APP23 Transgenic Mice. Neurochemical Research, 2008, 33, 1005-1010.	3.3	13
39	Progressive muscle atrophy with hypokalemic periodic paralysis and calcium channel mutation. Muscle and Nerve, 2008, 37, 120-124.	2.2	8
40	Acceptance of Enhanced Robotic Assistance Systems in People With Amyotrophic Lateral Sclerosisâ€“Associated Motor Impairment: Observational Online Study. JMIR Rehabilitation and Assistive Technologies, 2021, 8, e18972.	2.2	7
41	Experiences with assistive technologies and devices (ATD) in patients with amyotrophic lateral sclerosis (ALS) and their caregivers. Technology and Disability, 2019, 31, 203-215.	0.6	6
42	Differences in pain perception during open muscle biopsy and Bergstroem needle muscle biopsy. Journal of Pain Research, 2014, 7, 645.	2.0	5
43	Characteristics of pain and the burden it causes in patients with amyotrophic lateral sclerosis â€“ a longitudinal study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, , 1-8.	1.7	5
44	Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophy. Annals of Clinical and Translational Neurology, 2022, 9, 351-362.	3.7	5
45	A Multi-Center Cohort Study on Characteristics of Pain, Its Impact and Pharmacotherapeutic Management in Patients with ALS. Journal of Clinical Medicine, 2021, 10, 4552.	2.4	4
46	Caregiversâ€™ divergent perspectives on patientsâ€™ well-being and attitudes towards hastened death in Germany, Poland and Sweden. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 252-262.	1.7	2
47	Use and subjective experience of the impact of motor-assisted movement exercisers in people with amyotrophic lateral sclerosis: a multicenter observational study. Scientific Reports, 2022, 12, .	3.3	2
48	Reply: Adult-onset distal spinal muscular atrophy: a new phenotype associated with KIF5A mutations. Brain, 2019, 142, e67-e67.	7.6	1
49	Pain-Related Coping Behavior in ALS: The Interplay between Maladaptive Coping, the Patientâ€™s Affective State and Pain. Journal of Clinical Medicine, 2022, 11, 944.	2.4	1